Photo of Joanna Yeh, PhD

Joanna Yeh, PhD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-3580
Fax: (617) 726-5806


jyeh1@partners.org

Photo of Joanna Yeh, PhD

Massachusetts General Hospital
Phone: (617) 643-3580
Fax: (617) 726-5806


jyeh1@partners.org

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Joanna Yeh, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Joanna Yeh, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Assistant Biologist, Cardiology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

The Yeh lab is specialized in chemical biology and disease modeling using cell culture, mice and zebrafish. In addition, we are working at the forefront of genome engineering using zinc finger nuclease (ZFN), TALE nuclease and CRISPR-Cas technologies. Through a chemical screen in zebrafish, we have previously identified that cyclooxygenase-2 (COX-2) inhibitors can suppress the leukemia stem cells expressing the AML1-ETO oncogene. Based on this finding, the plan to conduct a clinical trial of a COX inhibitor in patients with acute myeloid leukemia (AML) is underway. Currently, Dr. Yeh’s laboratory is also investigating the metabolic pathways that regulate cholesterol homeostasis and dissecting the roles of oncogenic mutations in several metabolic genes including isocitrate dehydrogenase (IDH), fumarate hydratase (FH) and succinate dehydrogenase (SDH).

Publications

Powered by Harvard Catalyst
  • Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MV, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell 2015; 28:773-84. PubMed
  • Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JR, Aryee MJ, Joung JK. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 2015. PubMed
  • Metelo AM, Noonan HR, Li X, Jin Y, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Shin J, Carpenter AE, Yeh JR, Peterson RT, Iliopoulos O. Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model. J Clin Invest 2015; 125:1987-97. PubMed
  • Hwang WY, Fu Y, Reyon D, Gonzales AP, Joung JK, Yeh JR. Targeted Mutagenesis in Zebrafish Using CRISPR RNA-Guided Nucleases. Methods Mol Biol 2015; 1311:317-34. PubMed
  • Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A 2014; 111:E4869-77. PubMed
  • Hwang WY, Peterson RT, Yeh JR. Methods for targeted mutagenesis in zebrafish using TALENs. Methods 2014. PubMed
  • Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, Kung AL, Sweetser DA, Yeh JR. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway. Blood 2013; 121:4906-16. PubMed
  • Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013. PubMed
  • Hwang WY, Fu Y, Reyon D, Maeder ML, Kaini P, Sander JD, Joung JK, Peterson RT, Yeh JR. Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS ONE 2013; 8:e68708. PubMed
  • Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, Dehdashti SJ, Reinhold WC, Alemu L, Zhao L, Yeh JR, Sood R, Pommier Y, Austin CP, Jeang KT, Zheng W, Liu P. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction. Proc Natl Acad Sci U S A 2012; 109:14592-7. PubMed
  • Cade L, Reyon D, Hwang WY, Tsai SQ, Patel S, Khayter C, Joung JK, Sander JD, Peterson RT, Yeh JR. Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res 2012; 40:8001-10. PubMed
  • Helenius IT, Yeh JR. Small zebrafish in a big chemical pond. J Cell Biochem 2012; 113:2208-16. PubMed
  • Zhang Y, Yeh JR. In vivo chemical screening for modulators of hematopoiesis and hematological diseases. Adv Hematol 2012; 2012:851674. PubMed
  • Yeh JR. A Wnt inhibitor with a twist. Chem Biol 2011; 18:1518-20. PubMed
  • Sander JD, Cade L, Khayter C, Reyon D, Peterson RT, Joung JK, Yeh JR. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol 2011; 29:697-8. PubMed
  • Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, Curtin SJ, Blackburn JS, Thibodeau-Beganny S, Qi Y, Pierick CJ, Hoffman E, Maeder ML, Khayter C, Reyon D, Dobbs D, Langenau DM, Stupar RM, Giraldez AJ, Voytas DF, Peterson RT, Yeh JR, Joung JK. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 2010; 8:67-9. PubMed
  • Yeh JR, Munson KM. Zebrafish small molecule screen in reprogramming/cell fate modulation. Methods Mol Biol 2010; 636:317-27. PubMed
  • Yeh JR,Munson KM,Elagib KE,Goldfarb AN,Sweetser DA,Peterson RT. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 2009; 5:236-43. PubMed
  • Foley JE, Maeder ML, Pearlberg J, Joung JK, Peterson RT, Yeh JR. Targeted mutagenesis in zebrafish using customized zinc-finger nucleases. Nat Protoc 2009; 4:1855-67. PubMed
  • Dayyani F, Wang J, Yeh JR, Ahn EY, Tobey E, Zhang DE, Bernstein ID, Peterson RT, Sweetser DA. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperate with AML1-ETO to affect myeloid cell proliferation and survival. Blood 2008; 111:4338-47. PubMed
  • Yeh JR, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 2007; 135:401-10. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Joanna Yeh, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members